

03/29/99
J544 U.S. PTO

Please type a plus sign (+) inside this box → ☐ +

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>	Attorney Docket No. Miller.P001
	First Inventor or Application Identifier Jon M. Miller
	Title Substance to prevent or reverse weight gain induced by psychoactive agents
	Express Mail Label No. EL254093981US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	5. <input type="checkbox"/> Microfiche Computer Program (Appendix)	
2. <input checked="" type="checkbox"/> Specification [Total Pages 15] (preferred arrangement set forth below) - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the invention - Brief Summary of the invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies	
3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 1]	ACCOMPANYING APPLICATION PARTS 7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 8. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee) 9. <input type="checkbox"/> English Translation Document (if applicable) 10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 11. <input type="checkbox"/> Preliminary Amendment 12. <input type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 13. <input checked="" type="checkbox"/> * Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired (PTO/SB/09-12) 14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. <input type="checkbox"/> Other: _____	
4. Oath or Declaration [Total Pages 2] a. <input checked="" type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed) i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).		
* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).		
16. If a CONTINUING APPLICATION , check appropriate box, and supply the requisite information below and in a preliminary amendment: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: _____ Prior application information: Examiner _____ Group / Art Unit: _____ For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.		

17. CORRESPONDENCE ADDRESS	
<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)
or <input checked="" type="checkbox"/> Correspondence address below	
Name	Matthew J. Cohen
Address	21550 Oxnard St., Third Floor
City	Woodland Hills
State	CA
Zip Code	91367
Country	USA
Telephone	(818) 592-4040
Fax	(818) 703-0338

Name (Print/Type)	Matthew J. Cohen	Registration No. (Attorney/Agent)	42,426
Signature		Date	03/29/99

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR**

Docket Number (Optional)
Miller.P001

Applicant, Patentee, or Identifier: Jon M. Miller

Application or Patent No.: _____

Filed or Issued: _____

Title: Substance to prevent or reverse weight gain induced by psychoactive agents

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.
☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

Jon M. Miller

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Jon M. Miller
Signature of inventor

Signature of inventor

Signature of inventor

25 MARCH 1999
Date

Date

Date

BACKGROUND OF THE INVENTION

Field of the Invention:

The present invention relates to medications used for weight control. More particularly, the present invention relates to the use of a histamine H₂-receptor antagonist with antipsychotic and mood stabilizing drugs to control weight.

Description of the Prior Art:

Numerous innovations for substances to prevent or reverse weight gain have been provided in the past. Even though these innovations may be suitable for the specific individual purposes to which they address, they differ from the present invention because they fail to describe or claim at least one combination of the features depicted in the present invention. Even though these innovations may be suitable for the specific individual purposes to which they address, they would not be suitable for the purposes of the present invention as heretofore described.

SUMMARY OF THE INVENTION

The present invention prevents and reverses weight gain associated with the use of olanzapine and other antipsychotic drugs. The combination of psychoactive drugs and histamine H₂-receptor antagonists may represent a combined single dose delivery system or multiple drug regimen taken at preselected times. The psychoactive drugs are dosed as recommended by the manufacturer and the histamine H₂-receptor antagonists are dosed as for use in maintenance treatment of duodenal ulcer.

The types of problems encountered in the prior art are weight gain associated with the use of antipsychotic and mood stabilizing drugs, particularly olanzapine.

The problem was solved by the present invention because it was discovered that adding histamine H₂-receptor antagonists such as nizatidine or famotidine had a positive effect on weight gain associated with the use of antipsychotic and mood stabilizing drugs.

Accordingly, it is an object of the present invention to prevent or reduce weight gain in patients using antipsychotic and mood stabilizing medication.

In keeping with these objects, and with others which will become apparent hereinafter, one feature of the present invention resides, briefly stated, in the addition of histamine H₂-receptor antagonists to a regimen of psychoactive drugs such as the antipsychotic drugs, olanzapine, clozapine, risperidone, and quetiapine.

When the medication combination is designed in accordance with the present invention, weight gain is reduced or eliminated.

LIST OF REFERENCE NUMERALS

UTILIZED IN THE DRAWINGS

10 - substance to prevent or reverse weight gain (10)

12 - antipsychotic drug (12)

12A - olanzapine (12A)

12B - clozapine (12B)

12C - risperidone (12C)

12D - quetiapine (12D)

14 - mood stabilizing drug (14)

14A - divalproex sodium (14A)

14B - valproic acid (14B)

14C - mirtazapine (14C)

16 - histamine H₂ - receptor antagonist (16)

16A - nizatidine (16A)

16B - famotidine (16B)

16C - cimetidine (16C)

16D - ranitidine (16D)

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a block diagram of a substance to prevent or reverse weight gain.

FIG. 1 is a block diagram of a substance to prevent or reverse weight gain.

DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring to **FIGURE 1** which is a block diagram of a substance to prevent or reverse weight gain. The substance to prevent or reverse weight gain (10) having an antipsychotic drug (12) or mood stabilizing drug (14) in a concentration from 0.01% to 99.99% in combination with a histamine H2 - receptor antagonist (16) in a concentration from 99.99% to 0.01%.

The antipsychotic drug (12) is selected from a group consisting of olanzapine (12A), clozapine (12B), risperidone (12C), and quetiapine (12D). The antipsychotic drug (12) is typically in a concentration of 10% to 90%, 30% to 60% and 50%.

The mood stabilizing drug (14) is selected from a group consisting of divalproex sodium (14A), valproic acid (14B), and mirtazapine (14C). The mood stabilizing drug (14) is typically in a concentration of 10% to 90%, 30% to 60% and 50%.

The histamine H2 - receptor antagonist (16) is selected from a group consisting of nizatidine (16A), famotidine (16B), cimetidine (16C) and ranitidine (16D). The histamine H2 - receptor antagonist (16) is in a concentration of 90% to 10%. The histamine H2 - receptor antagonist (16) is typically in a concentration of 60% to 30% and 50%.

The substance to prevent or reverse weight gain (10) is formulated in the following combinations;

10 parts of olanzapine (12A) are combined with 150 parts of nizatidine (16A) or ranitidine (16D)

10 parts of olanzapine (12A) are combined with 20 parts of famotidine (16B)

10 parts of olanzapine (12A) are combined with 400 parts of cimetidine (16C)

3 parts of risperidone (12C) are combined with 75 parts of nizatidine (16A) or ranitidine (16D)

3 parts of risperidone (12C) are combined with 10 parts of famotidine (16B)

3 parts of risperidone (12C) are combined with 200 parts of cimetidine (16C)

100 parts of quetiapine (12D) are combined with 50 parts of nizatidine (16A) or ranitidine (16D)

100 parts of quetiapine (12D) are combined with 7 parts of famotidine (16B)

100 parts of quetiapine (12D) are combined with 135 parts of cimetidine (16C)

30 parts of mirtazapine (14C) are combined with 150 parts of nizatidine (16A) or ranitidine (16D)

30 parts of mirtazapine (14C) are combined with 20 parts of famotidine (16B)

30 parts of mirtazapine (14C) are combined with 400 parts of cimetidine (16C)

250 parts of divalproex sodium (14A) are combined with 50 parts of nizatidine (16A) or ranitidine (16D)

250 parts of divalproex sodium (14A) are combined with 7 parts of famotidine (16B)

250 parts of divalproex sodium (14A) are combined with 135 parts of cimetidine (16C)

It will be understood that each of the elements described above, or two or more together, may also find a useful application in other types of constructions differing from the type described above.

While the invention has been illustrated and described as embodied in a Substance to Prevent or Reverse Weight Gain Induced by Psychoactive Agents, it is not intended to be limited to the details shown, since it will be understood that various omissions, modifications, substitutions and changes in the forms and details of the device illustrated and in its operation can be made by those skilled in the art without departing in any way from the spirit of the present invention.

Without further analysis, the foregoing will so fully reveal the gist of the present invention that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this invention.

What is claimed as new and desired to be protected by Letters Patent is set forth in the appended claims.

[illegible]

1. A substance to prevent or reverse weight gain induced by psychoactive agents(10) comprising:

A) an antipsychotic drug (12) or mood stabilizing drug (14) in a concentration from 0.01% to 99.99%; and

B) a histamine H2 - receptor antagonist (16) in a concentration from 99.99% to 0.01%.

2. A substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 1, wherein the antipsychotic drug (12) is selected from a group consisting of olanzapine (12A), clozapine (12B), risperidone (12C), and quetiapine (12D).

3. A substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 1, wherein the mood stabilizing drug (14) is selected from a group consisting of divalproex sodium (14A), valproic acid (14B), and mirtazapine (14C).

4. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 1, wherein the histamine H₂ - receptor antagonist (16) is selected from a group consisting of nizatidine (16A), famotidine (16B), cimetidine (16C) and ranitidine (16D).

5. The substance to prevent or reverse weight gain (10) as described in claim 2, wherein the antipsychotic drug (12) is in a concentration of 10% to 90%.

6. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 5, wherein the antipsychotic drug (12) is in a concentration of 30% to 60%.

7. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 6, wherein the antipsychotic drug (12) is in a concentration of 50%.

8. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 3, wherein the mood stabilizing drug (14) is in a concentration of 10% to 90%.

9. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 8, wherein the the mood stabilizing drug (14) is in a concentration of 30% to 60%.

10. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 9, wherein the mood stabilizing drug (14) is in a concentration of 50%.

11. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein the histamine H2 - receptor antagonist (16) is in a concentration of 90% to 10%.

12. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 11, wherein the histamine H2 - receptor antagonist (16) is in a concentration of 60% to 30%.

13. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 12, wherein the histamine H2 - receptor antagonist (16) is in a concentration of 50%.

13. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 10 parts of olanzapine (12A) are combined with 150 parts of nizatidine (16A) or ranitidine (16D).

14. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 10 parts of olanzapine (12A) are combined with 20 parts of famotidine (16B).

15. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 10 parts of olanzapine (12A) are combined with 400 parts of cimetidine (16C).

16. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 3 parts of risperidone (12C) are combined with 75 parts of nizatidine (16A) or ranitidine (16D).

17. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 3 parts of risperidone (12C) are combined with 10 parts of famotidine (16B).

18. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 3 parts of risperidone (12C) are combined with 200 parts of cimetidine (16C).

19. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 100 parts of quetiapine (12D) are combined with 50 parts of nizatidine (16A) or ranitidine (16D).

20. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 100 parts of quetiapine (12D) are combined with 7 parts of famotidine (16B).

21. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 100 parts of quetiapine (12D) are combined with 135 parts of cimetidine (16C).

22. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 30 parts of mirtazapine (14C) are combined with 150 parts of nizatidine (16A) or ranitidine (16D).

23. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 30 parts of mirtazapine (14C) are combined with 20 parts of famotidine (16B).

24. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 30 parts of mirtazapine (14C) are combined with 400 parts of cimetidine (16C).

25. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 250 parts of divalproex sodium (14A) are combined with 50 parts of nizatidine (16A) or ranitidine (16D).

26. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 250 parts of divalproex sodium (14A) are combined with 7 parts of famotidine (16B).

27. The substance to prevent or reverse weight gain induced by psychoactive agents (10) as described in claim 4, wherein 250 parts of divalproex sodium (14A) are combined with 135 parts of cimetidine (16C).

ABSTRACT OF THE DISCLOSURE

A substance to prevent or reverse weight gain induced by psychoactive agents (10) having an antipsychotic drug (12) or mood stabilizing drug (14) in a concentration from 0.01% to 99.99% in combination with a histamine H₂ - receptor antagonist (16) in a concentration from 99.99% to 0.01%. The antipsychotic drug (12) is selected from a group consisting of olanzapine (12A), clozapine (12B), risperidone (12C), and quetiapine (12D). The antipsychotic drug (12) is typically in a concentration of 10% to 90%, 30% to 60% and 50%. The mood stabilizing drug (14) is selected from a group consisting of divalproex sodium (14A), valproic acid (14B), and mirtazapine (14C). The mood stabilizing drug (14) is typically in a concentration of 10% to 90%, 30% to 60% and 50%. The histamine H₂ - receptor antagonist (16) is selected from a group consisting of nizatidine (16A), famotidine (16B), cimetidine (16C) and ranitidine (16D). The histamine H₂ - receptor antagonist (16) is in a concentration of 90% to 10%. The histamine H₂ - receptor antagonist (16) is typically in a concentration of 60% to 30% and 50%.

ANTIPSYCHOTIC DRUG (12)

**OLANZAPINE (12A)
CLOZAPINE (12B)
RISPERIDONE (12C)
QUETIAPINE (12D)**

MOOD STABILIZING DRUG (14)

**DIVALPROEX SODIUM (14A)
VALPROIC ACID (14B)
MIRTAZAPINE (14C)**

**NIZATIDINE (16A) FAMOTIDINE (16B)
CIMETIDINE (16C) RANITIDINE (16D)**

HISTIMINE H2 - RECEPTOR ANTAGONIST (16)

FIG. 1

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	Miller.P001
	First Named Inventor	Jon M. Miller
	COMPLETE IF KNOWN	
	Application Number	/
	Filing Date	
	Group Art Unit	
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing	OR	<input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)
	Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Substance to prevent or reverse weight gain induced by psychoactive agents

the specification of which (Title of the Invention)

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer Number Bar Code Label here

Name	Registration Number	Name	Registration Number
Matthew J. Cohen	42,426		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label


OR ☒ Correspondence address below

Name	Matthew J. Cohen				
Address	21550 Oxnard St., Third Floor				
Address					
City	Woodland Hills	State	CA	ZIP	91367
Country	USA	Telephone	(818) 592-4040	Fax	(818) 703-0338

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])		Family Name or Surname					
Jon M.		Miller					
Inventor's Signature				Date	3/25/99		
Residence: City	Louisville	State	KY	Country	40242	Citizenship	USA
Post Office Address	8501 Rhett Butler Dr.						
Post Office Address							
City	Louisville	State	KY	ZIP	40242	Country	USA

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto